Amelie Eriksson Karlström received her PhD in 1997 at
the Stockholm University, Department of Neurochemistry and Neurotoxicology,
after graduate studies on solid phase peptide synthesis methodology.
This was followed by postdoctoral studies 1997-1999 at the Scripps
Research Institute, La Jolla, CA, where she was working on catalytic
antibodies and display technologies, with the objective of selecting
new functional catalyst and investigating the catalytic mechanism
of selected antibodies. Amelie Eriksson Karlström is presently
Associate Professor in Molecular Biotechnology at the Royal
Institute of Technology (KTH), School of Biotechnology, where
her research group is working on chemical protein engineering
for in vivo and in vitro diagnostic applications, using a combination
of chemical synthesis and recombinant technologies. She is also
the Director of the “AlbaNova VINN Excellence Centre for
Protein Technology (ProNova)“ (www.biotech.kth.se/pronova).
Research group: Nima Jokilaakso (PhD student),
Joel Lindgren (PhD student), Anna Perols (PhD student), Daniel
Rosik (PhD student) and Kristina Westerlund (PostDoc)
Teaching: Amelie Eriksson Karlström
is responsible for the undergraduate course “Drug
Development”, which is given in the 4th year of the
Biotechnology program at KTH.